Akeso's Gumokimab Monoclonal Antibody (IL-17) New Drug Application for the Treatment of Moderate to Severe Psoriasis Accepted by NMPA
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting monoclonal antibody gumokimab (AK111) has been ...
health.economictimes.indiatimes17h
Red light therapy shows promise for pain relief, inflammation, skin conditions - but other claims might be hyped
The umbrella term is called photobiomodulation therapy, which covers other colors, or wavelengths, that have health benefits.
InStyle on MSN4h
The Surprising Reason Your Hair Hurts When It’s Dirty
Dirty hair pain can be annoying, but it's easy to fix. Here's what causes it and how you can make it go away, according to ...
Bona Magazine20h
Colloidal oatmeal, the hack to your skin glow
Colloidal oatmeal might just be the secret your skincare routine has been missing. Known for its soothing and nourishing ...
centerforbiosimilars14h
Eye on Pharma: Teva, Formycon, Celltrion Biosimilar Updates in Global Markets
Three players in the biosimilar space have already sparked hope for the new year, with each having big business or regulatory ...